Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | CCNC | P24863 | 2/20 | 0.58 |
| ▸ | CDK8 | P49336 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28393 | 1.00 | SIGMAR1 (1.00) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| Piperazine SCHEMBL28228981 | 0.98 | SIGMAR1 (0.96) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| Hydrochloric Acid SCHEMBL1597474 | 0.98 | SIGMAR1 (0.96) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| SCHEMBL9644712 | 0.98 | SIGMAR1 (0.96) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| Piperazine SCHEMBL27760905 | 0.96 | SIGMAR1 (0.93) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| Formic Acid SCHEMBL7986200 | 0.93 | SIGMAR1 (0.86) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| SCHEMBL3423662 | 0.93 | SIGMAR1 (0.86) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| SCHEMBL12344755 | 0.91 | SIGMAR1 (0.83) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| Nitric Acid SCHEMBL14695754 | 0.90 | SIGMAR1 (0.81) | SIGMAR1HPGDRXFP1CCNCCDK8 | |
| Pyridine SCHEMBL28123146 | 0.90 | SIGMAR1 (0.81) | SIGMAR1HPGDRXFP1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683711-B1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORP (FI) | 2017-02-01 | — | — | EP | claimed |
| EP-1865949-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2012-11-14 | — | — | EP | claimed |
| US-4614739-A | Oxindole derivatives, pharmaceutical compositions and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-30 | — | — | US | claimed |
| EP-0062887-B1 | INDOLINONE-2 DERIVATIVES, PROCESS FOR THEIR PREPARATION AND NEURO-ANABOLIC MEDIUMS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-07-11 | — | — | EP | claimed |
| EP-0062887-A1 | Indolinone-2 derivatives, process for their preparation and neuro-anabolic mediums containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-10-20 | — | — | EP | claimed |
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-4614739-A | Oxindole derivatives, pharmaceutical compositions and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-30 | — | — | US | disclosed |
| US-4542148-A | 2-Oxo-3-phenyl indole derivatives, drugs having a neuroanabolic action containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | disclosed |
| EP-0062887-B1 | INDOLINONE-2 DERIVATIVES, PROCESS FOR THEIR PREPARATION AND NEURO-ANABOLIC MEDIUMS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0062887-A1 | Indolinone-2 derivatives, process for their preparation and neuro-anabolic mediums containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885HPGD 1544/4885RXFP1 4521/4885 |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885HPGD 1544/4885RXFP1 4521/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885HPGD 1544/4885RXFP1 4521/4885 |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885HPGD 1544/4885RXFP1 4521/4885 |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | SIGMAR1 4271/4885HPGD 1544/4885RXFP1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.